Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)’s share price traded down 4.4% on Wednesday . The stock traded as low as $146.75 and last traded at $147.50, with a volume of 219,710 shares changing hands. The stock had previously closed at $154.31.

Several equities analysts recently weighed in on the stock. Wedbush reissued a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Saturday. Cantor Fitzgerald assumed coverage on Intercept Pharmaceuticals in a report on Wednesday, July 6th. They set a “sell” rating and a $58.00 price target for the company. Robert W. Baird reaffirmed an “outperform” rating and set a $332.00 price target on shares of Intercept Pharmaceuticals in a report on Wednesday, June 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $350.00 price target on shares of Intercept Pharmaceuticals in a report on Wednesday, June 1st. Finally, Wells Fargo & Co. reaffirmed a “buy” rating on shares of Intercept Pharmaceuticals in a report on Tuesday, May 31st. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $203.08.

The stock’s 50-day moving average price is $148.33 and its 200-day moving average price is $133.78. The firm’s market cap is $3.57 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($5.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.60) by $1.57. During the same quarter in the previous year, the company posted ($1.78) earnings per share. On average, equities analysts forecast that Intercept Pharmaceuticals Inc. will post ($16.82) EPS for the current year.

In other news, CEO Mark Pruzanski sold 714 shares of the company’s stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $145.11, for a total transaction of $103,608.54. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Lisa Bright sold 251 shares of the company’s stock in a transaction on Wednesday, May 25th. The shares were sold at an average price of $137.50, for a total value of $34,512.50. Following the transaction, the insider now directly owns 18,855 shares in the company, valued at approximately $2,592,562.50. The disclosure for this sale can be found here.

Several hedge funds and institutional investors have recently modified their holdings of ICPT. BB Biotech AG boosted its position in shares of Intercept Pharmaceuticals by 21.4% in the fourth quarter. BB Biotech AG now owns 255,719 shares of the biopharmaceutical company’s stock worth $38,192,000 after buying an additional 45,000 shares in the last quarter. Alps Advisors Inc. purchased a new position in shares of Intercept Pharmaceuticals during the fourth quarter worth approximately $4,787,000. South Dakota Investment Council boosted its position in shares of Intercept Pharmaceuticals by 6.8% in the fourth quarter. South Dakota Investment Council now owns 36,200 shares of the biopharmaceutical company’s stock worth $5,406,000 after buying an additional 2,300 shares in the last quarter. ProShare Advisors LLC boosted its position in shares of Intercept Pharmaceuticals by 5.9% in the fourth quarter. ProShare Advisors LLC now owns 20,213 shares of the biopharmaceutical company’s stock worth $3,019,000 after buying an additional 1,130 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its position in shares of Intercept Pharmaceuticals by 2.2% in the fourth quarter. New York State Common Retirement Fund now owns 37,400 shares of the biopharmaceutical company’s stock worth $5,586,000 after buying an additional 800 shares in the last quarter.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Company’s product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.